NCT07329972

A Study to Evaluate the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of ZN-A-1041 in Healthy Participants

A Phase 1, Open-label, Randomized, Crossover Study to Evaluate the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of ZN-A-1041 Tablet(s) in Healthy Participants

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 48 (estimated)
• Sponsor: Genentech, Inc. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

This study is a phase 1, open-label, randomized, four-period crossover study to evaluate the effect of food and rabeprazole on the ZN-A-1041 tablet formulation in healthy male and female participants.

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	ZN-A-1041 Formulation 1	Participants will receive a single dose of ZN-A-1041 Formulation 1 on each specified treatment.
DRUG	ZN-A-1041 Formulation 2	Participants will receive a single dose of ZN-A-1041 Formulation 2 on each specified treatment.
DRUG	Rabeprazole	Participants will receive an oral administration of rabeprazole twice daily (BID) on days 9, 10, 15, and 16 and a single dose on Days 11 and 17.

Timeline

• Start date: 2025-11-21
• Primary completion: 2026-08-08
• Completion: 2026-08-12
• First posted: 2026-01-09
• Last updated: 2026-04-02

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study